ストックスクリーナーアプリを入手
1.825
19.03%
-0.435
前日終値:
$2.26
開ける：
$2.28
24時間の取引高:
5.54M
Relative Volume:
5.10
時価総額：
$101.42M
収益：
-
当期純損益:
$-67.68M
株価収益率:
-1.0549
EPS:
-1.73
ネットキャッシュフロー:
$-54.24M
1週間 パフォーマンス:
-51.59%
1か月 パフォーマンス:
-59.51%
6か月 パフォーマンス:
-84.99%
1年 パフォーマンス:
-89.61%
1日の値動き範囲:
$1.76
$2.30
1週間の範囲:
$1.76
$3.84
52週間の値動き範囲:
$1.76
$26.35
Cabaletta Bio Inc Stock (CABA) Company Profile
CABA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CABA | 1.8297 | 101.42M | 0 | -67.68M | -54.24M | -1.73 |
| VRTX | 449.26 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.72 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 600.42 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.28 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-07-18 | 開始されました | Guggenheim | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-01-08 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 開始されました | Cowen | Outperform |
| 2019-11-19 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Cabaletta Bio Inc (CABA) 最新ニュース
Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MyChesCo
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN
Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com
Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks
Cabaletta reports promising autoimmune therapy results By Investing.com - Investing.com Canada
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Cabaletta reports promising autoimmune therapy results - Investing.com
Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World
Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat
Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK
Cabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartzy
T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com
Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
UBS Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation - MSN
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate - Yahoo Finance
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in October - MarketBeat
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Hol - GuruFocus.com
Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Drops By 16.7% - MarketBeat
Trading Day Review: Cabaletta Bio Inc (CABA) Gains Momentum, Closing at 4.21 - The Dwinnex
Millennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
UBS sees significant upside for Cabaletta Bio despite recent share decline - Investing.com India
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Healthy Upside Potential: Cabaletta Bio Inc (CABA) - SETE News
UBS sees significant upside for Cabaletta Bio despite recent share decline By Investing.com - Investing.com South Africa
Cabaletta Bio (NASDAQ:CABA) Now Covered by Analysts at UBS Group - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
A Guide To The Risks Of Investing In Cabaletta Bio Inc (CABA) - Knox Daily
Cabaletta Bio Inc (CABA) stock analysis: A comprehensive overview - US Post News
Cabaletta Bio Outlines Future Trials and Development Strategy - TipRanks
Squarepoint Ops LLC Has $2.36 Million Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Marshall Wace LLP Grows Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Get in on Cabaletta Bio Inc’s (CABA) buy-in window today! - SETE News
Should investors be concerned about Cabaletta Bio Inc (CABA)? - US Post News
Cabaletta Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Cabaletta Bio secures lease terms through August 2026 - Investing.com India
Cabaletta Bio secures lease terms through August 2026 By Investing.com - Investing.com South Africa
Ratios Reveal: Breaking Down Cabaletta Bio Inc (CABA)’s Financial Health - The Dwinnex
Perceptive Advisors LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc (CABA) 財務データ
収益
当期純利益
現金流量
EPS
Cabaletta Bio Inc (CABA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | See Remarks |
Jan 19 '24 |
Sale |
19.59 |
11,000 |
215,439 |
20,000 |
| Binder Gwendolyn | See Remarks |
Dec 19 '23 |
Option Exercise |
1.01 |
11,000 |
11,110 |
31,000 |
| Binder Gwendolyn | See Remarks |
Dec 19 '23 |
Sale |
21.89 |
11,000 |
240,789 |
20,000 |
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):